Introduction and Risk Assessment
In developed countries Breast Cancer (BC) occurs in one out of eight women during her lifetime, estimating the life expectancy of 85 years. About 10% of BC are associated with genetic risk factors, essentially mutations of BRCA1 and BRCA2, however but the majority of BC are sporadic. Risk factors for BC are primarily related to age and to estrogen exposure (early menarche, late menopause, nulliparity, use of exogenous hormones), in addition high risk population also include women with atypical hyperplasia, and patients with ductal or lobular carcinoma in situ.
The lifetime cumulative risk of breast cancer for women with BRCA1 or BRCA2 mutations is very high ranging from 45 to 65%, this population has an elevated ovarian cancer risk as well 1 . The ovarian cancer estimated lifetime risks is 36-46% and 10-27% in BRCA1 and BRCA2 mutation carriers, respectively. Therefore for these women a close surveillance is suggested as well as medical and surgical options, including chemoprevention, bilateral salpingo-oophorectomy and mastectomy.
Outside of genetic risk factors, for general population, it's important to identify women at high risk of breast cancer: patients with previous thoracic RT < 30 y of age, women diagnosed with lobular carcinoma in situ, women with an estimated 5-year breast cancer risk ≥1.7% 2 . Several mathematical models to estimate this risk have been proposed, currently the most used is the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool which is a modified version of the Gail model that consider age, race, age at first pregnancy, family history and history of atypical hyperplasia; individuals with a 5-year risk of 1.66% or greater are considered at risk 3 . All the models have a limited reliability and, as a matter of fact, up to 60% of BC occurs in women with no known risk factors; the available models do not include some risk factors such as obesity, diet, mammographic density and use of HRT. A higher accuracy could be obtained by incorporating information on genotypes as well.
A recent report published on the new England journal of medicine 4 underlines the importance of atypical hyperplasia as an independent factor for the inclusion of patients in chemoprevention programs. Atypical hyperplasia is a high-risk benign lesion that is found in approximately 10% of biopsies with benign findings. In studies with long-term follow-up, atypical hyperplasia has been shown to confer a relative risk for future breast cancer of 4. Another large cohort study at the Mayo Clinic 5 published on 2014, confirms the cumulative high risk of breast cancer among women with atypical hyperplasia. Indeed, 25 years after a biopsy showing atypical hyperplasia, breast cancer (either in situ or invasive) developed in 30% of the women, with greater numbers of foci associated with a higher risk. Hartman and co. conclude suggesting that absolute risk data about women diagnosed with atypical hyperplasia should be used instead of models to describe breast-cancer risk in this population. Guidelines for high-risk women should be updated to include women with atypical hyperplasia. Analyses of data from the subgroup of women with atypical hyperplasia were performed in four of the placebo-controlled trials (NSABP P-1, MAP.3, IBIS-I, and IBIS-II). A total of 2009 women with atypical hyperplasia were randomly assigned to receive an active agent or placebo in these trials. Relative-risk reductions in the atypical hyperplasia subgroup ranged from 41 to 79%, which suggested an even greater benefit than in the total population treated with active agent in these trials.
Women with a life expectancy of ≥10 years and no diagnosis or history of breast cancer who are considered to be at increased risk for breast cancer based on any of the above-mentioned assessments, should receive individualized counseling to decrease breast cancer risk. Strategies for prevention of breast cancer include: lifestyle factors (avoidance of obesity, maintaining physical activity, moderation in alcohol intake), chemoprevention therapy with risk-reduction agents and risk-reduction surgery 2 .
Risk reduction mastectomy (RRM)
Retrospective analyses with median follow-up periods of 13 to 14 years have indicated that bilateral risk-reducing mastectomy decreased the risk of developing breast cancer by approximately 90% in moderate-and high-risk women and in known BRCA1/2 mutation carriers 6 . Further results from smaller prospective studies with shorter follow-up support the conclusion that RRM provides a high degree of protection against breast cancer in women with a BRCA1/2 mutation. A recent meta-analysis including 2635 patients, demonstrated a significant risk reduction of breast cancer incidence in BRCA1 and BRCA2 mutation carriers receiving RRM (HR 0.07; 95 % CI 0.01-0.44; p = 0.004).
In the 2007 guidelines issued by the Society of Surgical Oncology, indications for bilateral prophylactic mastectomies in Patients without a Cancer Diagnosis included: BRCA mutations or other genetic susceptibility genes, strong family history with no demonstrable mutation, histological risk factors (including atypical ductal or lobular hyperplasia, or lobular carcinoma in situ confirmed on biopsy); a further indication was a difficult surveillance 7 . The position Statement states that rarely, bilateral prophylactic mastectomies may be warranted for an exceptional patient with no family history or high-risk histology such as patient with extremely dense fibronodular tissue that is difficult to evaluate with standard breast imaging, several prior breast biopsies for clinical and/or mammographic abnormalities, and strong concern about breast cancer risk. In the same guidelines, potential indications for prophylactic contralateral mastectomy in patients with a current or previous diagnosis of breast cancer were: risk reduction (see indications as listed above), difficult surveillance (patients with clinically and mammographically dense breast tissue or diffuse indeterminate microcalcifications in the contralateral breast), or reconstructive issues (symmetry/balance).
The 2017 NCCN Breast Cancer Risk Reduction Panel supports the use of RRM for carefully selected women at high risk for breast cancer who desire this intervention, exclusively considering BRCA1/2 or other genetic mutations and previous history of LCIS 2 Bilateral risk-reducing salpingo-oophorectomy (RRSO)
The absence of reliable methods of early detection and the poor prognosis associated with advanced ovarian cancer have lent support for the performance of bilateral risk-reducing salpingo-oophorectomy (RRSO) that decreases the risk of developing ovarian and fallopian cancer by 85-95% in BRCA1/2 mutation carriers when performed before age 50 8 . RRSO is also reported to reduce by approximately 50% the risk for breast cancer in BRCA mutation carriers when performed in premenopausal age. The results of several studies suggest that RRSO may be associated with a greater reduction in breast cancer risk for BRCA1 mutation carriers compared with BRCA2 mutation carriers 9 -10 .
The decreased hormonal exposure following surgical removal of the ovaries is the basis for the reductions in breast cancer risk after RRSO; results from Eisen et al suggest the reductions in breast cancer risk is greater when the surgery is performed in younger women: (OR 0.41 (95% CI, 0.25-0.68) for RRSO performed at age 40 years or younger versus odds ratio 0.47 (95% CI, 0.28-0.80) for RRSP performed in carriers aged 41-50 years). Non significant risk reduction of breast cancer was found for women aged 51 years or older 10 . Data are limited about the optimal age for RRSO. Considering that the mean age at diagnosis of ovarian cancer is 50.8 year for BRCA1/2 mutation carriers 11 Following prophylactic salpingo-oophorectomy a 1-4.3% residual risk for a primary peritoneal carcinoma in BRCA1 and BRCA2 mutation carriers still exists 13 . It cannot be excluded that in some cases peritoneal carcinoma foci are actually metastases of sub-clinical disease that was present at the time of surgery (occult carcinomas), so that undiagnosed cancers at the time of surgery will be considered primary peritoneal cancer when they become clinically apparent. Possibly fewer peritoneal cancers will be diagnosed after salpingo-oophorectomy if the comprehensive pathology review of the specimens is performed on all patients 14 . Fisch et al in paper based on a series of 159 female BRCA1 or BRCA2 carriers who underwent prophylactic oophorectomy, showed that 2-10% of BRCA1/2 carriers who undergo prophylactic salpingo-oophorectomy will be found to have occult carcinomas if the ovaries and the tubes are rigorously examined. No cancers were detected among women who had the operation at age 39 or younger 15 . The conclusion is that a rigorous operative and pathologic protocol for RRSO increases the detection rate of occult ovarian malignancy in BRCA mutation carriers, influencing the postoperative management whit additional staging, chemotherapy, and followup in affected women. Also the peritoneal lavage cytology can detect occult carcinoma at the time of RRSO 16 and should always be performed 2 . The additional benefit of concurrent hysterectomy is not clear. Even if careful ligation of the fallopian tube at the uterine origin is performed, a small portion of interstitial fallopian tube in the cornua of the uterus is left in situ if hysterectomy is not performed, however, in the largest study on fallopian tube cancer to date, 92% of cancers originated in the distal or midportion of the tube. The concurrent hysterectomy, can simplify HRT allowing estrogen only supplementation and can reduce the endometrial cancer risk associated with Tamoxifen treatment for a previous breast cancer 12 analysis of 13 studies shows a reduced risk of epithelial ovarian cancer by 34%. The protective effect of tubal ligation was confirmed even in a subgroup of women 10-14 years after the procedure. The risk reduction was confirmed for the endometrioid and serous cancers but not for mucinous 19 .
Treatment of menopausal symptoms in BRCA mutation carriers
The absence of reliable methods of early detection and the poor prognosis associated with advanced ovarian cancer have lent support for the performance of bilateral risk reduction RRSO, however there are many concerns and worries about the resulting premature menopause. Premenopausal oophorectomy is also associated with an increased risk of osteopenia, osteoporosis and fracture. Following oophorectomy, there is an increased prevalence of osteoporosis within three to six years of surgery, the loss of trabecular bone has been reported to be as high as 20% during the first 18 months following surgery. Several recent cross-sectional studies have examined bone health after salpingo-oophorectomy in women with a BRCA mutation. Cohen et al. published a study of 226 BRCA carriers after salpingo-oophorectomy 21 : among women who underwent surgery before the age of 50 years, high rates of osteopenia (62%) and osteoporosis (9%) were reported. The 2010 Canadian guidelines for diagnosis and management of osteoporosis proposes bone density measurement with DXA at the time of salpingo-oophorectomy and again 1-2 years after surgery; the timing of further bone density measurements should be individualized based on the results of these two measurements;
to prevent osteoporosis¸ a recommended daily intake of 1500 mg calcium from dietary and supplemental sources and supplementation with 800 IU/day of vitamin D daily is suggested. In women with premature menopause Hormone Replacement Therapy (HRT), if not contraindicated, is advised to preserve bone mineral density, however the duration of use is not clear 2 .
Bilateral oophorectomy has also been shown to be a risk factor for coronary heart disease. A positive association between bilateral oophorectomy and increased risk of cardiovascular disease has been observed in a number of observational studies, including the Nurse's Health Study (rate ratio 2.2) and the Mayo Clinic Cohort of Oophorectomy and Aging (HR 1.4) . A recent study 22 links BRCA1 gene function with cardiovascular function, ( RCA1 gene products work to prevent DNA damage). The loss of BRCA1 in cardiomyocytes may results in adverse cardiac remodeling, poor ventricular function and increased mortality in response to ischemic or genotoxic stress. Therefore BRCA1-mutated women may be at an increased risk for cardiovascular disease. Even if there are no clinical studies to date to evaluate this issue. Also in this context HRT may mitigate the increase in cardiovascular risk associated with surgical menopause.
Several studies show that short-term HRT use does not negate the protective effect of RRSO on subsequent breast cancer risk in BRCA1/2 mutation carriers 23 . In a matched case-control study of 472 postmenopausal women with a BRCA1 mutation, Eisen et al. examined whether or not the use of HRT was associated with subsequent risk of breast cancer 24 . The adjusted OR for breast cancer associated with ever use of HRT compared with never use was 0.58 (95% CI 0.35 -0.96; P = .03), they concluded that HRT use was not associated with increased risk of breast cancer; indeed, in BRCA1 mutated women, it was associated with a decreased risk. In a recent review Marchetti and al 25 conclude that HRT generally reduces symptoms related to surgical menopause, short-term HRT seems to improve quality of life and does not seem to have an adverse effect on oncologic outcomes in BRCA1 and BRCA2 mutation carriers without a personal history of breast cancer. The 2013 NICE guidelines recommends HRT for women with no personal history of breast cancer, including BRCA1 or BRCA2 mutation carriers, having had bilateral salpingo-oophorectomy before their natural menopause. They should take combined HRT or Estrogens only depending on having the uterus or not, until the time they would have expected natural menopause.
Estrogen therapy, however, is contraindicated for breast cancer survivors 26 . The Stockholm trial 27 was prematurely stopped in 2003 when the parallel HABITS trial 28 reported a higher recurrence rate in breast cancer patients who received systemic estrogens compared to women treated with placebo. At 4 years of follow-up, the HABITS study still found an increased risk of recurrence 29 whereas a recent updated analysis of the data from the Stockholm trial at 10.8 years of follow-up did not show any excess of recurrence risk 30 . An alternative compound to conventional estrogen/progestogen treatment, tibolone, was tested versus placebo in the LIBERATE trial, showing a significant superiority to placebo in reducing vasomotor symptoms and improving sleep quality, sexual behaviour, mood and attraction, but unfortunately also a significant increase in the recurrence rate 31 .
Because of this concern, research efforts have focused on non-hormonal drugs to alleviate climacteric symptoms. Several substances have been tested: some of them give similar results to placebo, that in itself provides a response in around 20-30% of women, others have shown promising results.
Conclusions
Women with a life expectancy ≥10 years and no diagnosis/history of breast cancer who are considered to be at increased risk for breast cancer, should receive counseling to decrease breast cancer risk, considering: lifestyle factors, therapy with risk-reduction agents, risk-reduction surgery (in BRCA1/2 mutation carriers).
Bilateral risk reducing mastectomy decreases the risk of developing breast cancer by at least 90%; it should be proposed to carefully selected women at high risk for breast cancer considering BRCA1/2 or other genetic mutations and previous history of LCIS. In current practice, atypical hyperplasia is not an indication for prophylactic mastectomy.
Bilateral risk reducing salpingo-oophorectomy decreases the risk of developing ovarian and fallopian cancer by 85-95% and breast cancer by 50% in BRCA1/2 mutation carriers when performed in premenopausal age. Peritoneal washing should be performed at surgery and pathologic assessment should include fine sectioning of the ovaries and fallopian tubes. The additional benefit of concurrent hysterectomy is not clear at the time. In women with no personal history of breast cancer short-term
